Pharmaceutical Report Library l Report Store l Pharma Intelligence

Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

$599.00

This interview covers the current treatment of multiple myeloma in the US, and the main areas of unmet need.

January 18, 2019

Find out more

Spain, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Spain; incidence and prevalence figures are compared with those of the Benelux countries

November 1, 2012

Find out more

Epclusa

Epclusa ([sofosbuvir + velpatasvir]; Gilead) is a once-daily, fixed-dose combination of Gilead’s nucleotide NS5B polymerase inhibitor, sofosbuvir; and the company’s second-generation NS5A inhibitor, velpatasvir.

November 6, 2017

Find out more

Immuno-Oncology Overview

$7,500.00

Immuno-oncology is an area of medicine that focuses on the development of therapies that improve the body’s ability to generate an immune response against cancer (Eggermont and Finn, 2012).

December 13, 2017

Find out more

adagloxad simolenin

Adagloxad simolenin (OBI Pharma) is a carbohydrate-based vaccine comprised of Globo-H conjugated to keyhole limpet hemocyanin. Upon exposure to the synthetic Globo-H vaccine and an immunological adjuvant, the immune system mounts IgM and IgG responses against Globo-H hexasaccharide.

February 26, 2020

Find out more

Market Spotlight: Huntington’s Disease

$1,318.00

This Market Spotlight report covers the Huntington’s Disease market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

November 18, 2021

Find out more

DCVax-L

DCVax-L (Northwest Biotherapeutics) is a dendritic cell vaccine in development for the treatment of glioblastoma multiforme (GBM). It is a personalized immunotherapy that utilizes patients’ own dendritic cells to stimulate…

April 13, 2016

Find out more

Reasanz

Reasanz (serelaxin; Novartis) has not yet obtained approval in the US, Japan, or EU for the treatment

of acute decompensated heart failure (ADHF), despite its fast track and breakthrough therapy

designations from the US Food and Drug Administration (FDA).

March 16, 2016

Find out more

Zyvox

Pfizer developed Zyvox (linezolid) as the first oxazolidinone antimicrobial agent. The drug gained its first regulatory approval for the treatment of complicated skin and skin structure infections (cSSSI) in the US market in 2000.

June 19, 2015

Find out more

Interventional Cardiology: Implantable Pacemaker Products

$4,750.00

In 2020, the global market for implantable pacemaker products totaled nearly $3.9bn, with dual-chamber products accounting for nearly 75% of sales. Over the forecast period covered by this report, single-chamber pacemaker devices are expected to experience greater growth than the dual-chamber market, advancing at a CAGR of approximately 6.8%. Drivers include a growing prevalence of cardiovascular disease due to the aging population, the development of leadless pacemaker systems, and expanded indications. Additionally, there is strong evidence of a correlation between COVID-19 and the development of atrial arrythmias.

November 11, 2021

Find out more

Sarilumab

Sarilumab (Sanofi/Regeneron) is a human monoclonal antibody interleukin (IL)-6 receptor antagonist in Phase III development for rheumatoid arthritis.

March 24, 2015

Find out more

Spinal Fusion Implanted Instrumentation Market

$599.00

This medical market and technology report provides a comprehensive discussion of implanted instrumentation for spinal fusion.

February 28, 2018

Find out more

Tropifexor

FXR is a nuclear receptor that regulates bile acid metabolism and signaling. Activation of the receptor inhibits bile acid synthesis from cholesterol via cytochrome P450 7A1 and increases bile acid conjugation, transport, and excretion. This protects the liver from the potentially harmful effects caused during bile acid accumulation. Tropifexor (Novartis/Pfizer) is a novel, highly potent, non-bile acid FXR agonist. It has demonstrated potent activity in rodent Parkinson’s disease models by measuring the induction of FXR target genes in tissues.

July 22, 2019

Find out more

Disease Analysis: Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.

December 21, 2021

Find out more

Disease Analysis: NHL: Follicular Lymphoma

Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL) specifically originating from centrocyte and centroblast B cells and usually beginning in the lymph nodes. The disease is among the most common forms of NHL alongside diffuse large B-cell lymphoma (DLBCL), accounting for approximately 35% of all NHLs.

July 5, 2021

Find out more

Report library

Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

Spain, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

Epclusa

Immuno-Oncology Overview

adagloxad simolenin

Market Spotlight: Huntington’s Disease

DCVax-L

Reasanz

Zyvox

Interventional Cardiology: Implantable Pacemaker Products

Sarilumab

Spinal Fusion Implanted Instrumentation Market

Tropifexor

Disease Analysis: Triple-Negative Breast Cancer

Disease Analysis: NHL: Follicular Lymphoma